Table 2.

Clinical characteristics and outcomes of infliximab treatment in 5 Crohn’s disease patients with severe gastrointestinal bleeding as a first presentation

No.	Age (yr)	Sex	Presenting symptom	Dropped rate of Hb (g/dL)	PRBC (unit)	Location	Characteristic of lesion	Infliximab therapy	Bleeding controlled in	Follow-up (mo)
1	59	M	Diarrhea and abdominal pain (10 d) GIB (1 d)	from 10 to 8 in 3 d	6	Ileum	Multiple ileal ulcers with oozing and one visible vessel	Infliximab 5 mg/kg (d0, week 2)	1 d	24
2	86	M	GIB (1 d)	from 12 to 8.5 in 4 d	7	Ileum	Multiple ileal ulcers with oozing	Infliximab 5 mg/kg (d0, week 2)	1 d	36
3	71	F	Diarrhea and abdominal pain (10 d) GIB	from 13 to 10 in 3 d	3	ileum	Multiple ileal ulcers with oozing	Infliximab 5 mg/kg (d0, week 2)	1 d	12
4	50 yr	F	Diarrhea and abdominal pain (14 d) GIB (1 d)	from 14 to 10 in 3 d	2	Ileum and jejunum	Multiple ileal and jejunum ulcers with oozing	Infliximab 5 mg/kg (d0, week 2)	1 d	36
5	71 yr	M	1st episode GIB from ileal ulcer (1 mo)Recurrent GIB (1 d)	from 11 to 6.5 in 5 d	6	Ileum	Multiple ileal ulcers with oozing and one visible vessel	Infliximab 5 mg/kg (single dose )	1 d	24

CD: Crohn’s disease; GIB: Gastrointestinal bleeding; Hb: Hemoglobin; 5-ASA: 5-aminosalicylates; PRBC: Packed red blood cell; M: Male; F: Female.